Mvasi Approval History
FDA Approved: Yes (First approved September 14, 2017)
Brand name: Mvasi
Generic name: bevacizumab-awwb
Dosage form: Injection
Company: Amgen Inc.
Treatment for: Non-Small Cell Lung Cancer, Colorectal Cancer, Glioblastoma Multiforme, Renal Cell Carcinoma, Cervical Cancer
Mvasi (bevacizumab-awwb) is an anti-vascular endothelial growth factor A (anti-VEGF) monoclonal antibody biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer including metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, and cervical cancer.
Development History and FDA Approval Process for Mvasi
|Sep 14, 2017||FDA Approves Mvasi (bevacizumab-awwb), a Biosimilar to Avastin|
|Nov 15, 2016||Amgen and Allergan Submit Biosimilar BLA for ABP 215 to U.S. FDA|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.